Metraipolis › archive › dc_14e9bc3401cb
Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with… — Europe PMC PMID:42278459
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42278459
- DOI
- 10.3390/ijms27114933
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-08T14:41:18.154Z
- SHA-256 of the archived text
75543a7de89767e676bc15f8d0df2bd4d7e53c19913644ef429abc843277c491- Stable URL of this page
https://metraipolis.com/documento/dc_14e9bc3401cb
How to cite
Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with… — Europe PMC PMID:42278459 — Europe PMC (en), https://europepmc.org/article/MED/42278459 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_14e9bc3401cb (Metraipolis archive dc_14e9bc3401cb, sha256 75543a7de89767e676bc15f8d0df2bd4d7e53c19913644ef429abc843277c491)
BibTeX
@misc{dc14e9bc3401cb,
title = {Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with… — Europe PMC PMID:42278459},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42278459},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_14e9bc3401cb; sha256 75543a7de89767e676bc15f8d0df2bd4d7e53c19913644ef429abc843277c491},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42278459. Agents can read the archived copy with the MCP tool read_document.